The position of combined medical treatment in acromegaly
Arch. endocrinol. metab. (Online)
; 63(6): 646-652, Nov.-Dec. 2019.
Article
in English
| LILACS
| ID: biblio-1055016
Responsible library:
BR1.1
ABSTRACT
ABSTRACT Advances in combination medical treatment have offer new perspectives for acromegaly patients with persistent disease activity despite receiving the available medical monotherapies. The outcomes of combination medical treatment may reflect both additive and synergistic effects. This review focuses on combination medical treatment and its current position in acromegaly, based on clinical studies evaluating the efficacy and safety of combined medical treatment(s) and our own experiences with combination therapy. Arch Endocrinol Metab. 2019;63(6)646-52
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Somatostatin
/
Receptors, Somatostatin
/
Dopamine Agonists
/
Human Growth Hormone
Aspects:
Patient-preference
Limits:
Humans
Language:
English
Journal:
Arch. endocrinol. metab. (Online)
Journal subject:
Endocrinology
/
Metabolism
Year:
2019
Document type:
Article
Affiliation country:
Hungary
Institution/Affiliation country:
Erasmus University Medical Center Rotterdam/hungria